Determinants of cervical pre-cancer and cancer among women attending cervical cancer clinic in Felege Hiwot Comprehensive Specialized Hospital, Northwest Ethiopia

Alemayehu A. Mengestu; Melkamnesh A. Yemenu

doi:10.18203/issn.2454-2156.IntJSciRep20253325

Authors

Alemayehu A. Mengestu Health Research Development Directorate, Amhara Public Health Institute, Amhara, Ethiopia
Melkamnesh A. Yemenu Department of Biology, Bahir Dar University, Amhara, Ethiopia

DOI:

https://doi.org/10.18203/issn.2454-2156.IntJSciRep20253325

Keywords:

Cervical cancer, Precancerous lesions, HPV, VIA, Ethiopia, CIN II , Risk factors

Abstract

Background: Cervical cancer is a leading cause of cancer-related morbidity and mortality in low- and middle-income countries, with over 85% of cases occurring in these settings. In Ethiopia, it ranks as the second most common cancer among women. This study examined determinants of cervical pre-cancer and cancer among women attending Felege Hiwot Comprehensive Specialized Hospital (FHCSH) in northwest Ethiopia.

Methods: A facility-based cross-sectional study was conducted among 350 women aged 21–65 years at FHCSH. Data on socio-demographic, reproductive, behavioral, and clinical characteristics were collected using a standardized questionnaire. Participants underwent visual inspection with acetic acid (VIA), high-risk human papillomavirus (HR-HPV) DNA testing, and histopathology. Cervical intraepithelial neoplasia grade II or worse (CIN II+) was the primary outcome. Logistic regression identified associated factors (p<0.05).

Results: Cervical cancer and pre-cancer prevalence were 12% and 20%, respectively. HR-HPV infection was found in 39% of participants. CIN II+ was strongly associated with HPV infection (OR=90.9), VIA positivity (OR=79.2), age ≥30 years (OR=8.1), history of sexually transmitted infections (OR=9.8), hormonal contraceptive use (OR=3.3), comorbidities (OR=2.9), early sexual debut, multiple sexual partners, non-condom use, and high parity.

Conclusion: Both modifiable and non-modifiable factors contribute to cervical pre-cancer and cancer in Ethiopia. Strengthening HPV vaccination, promoting safer sexual practices, integrating STI management, and expanding VIA and HPV testing are critical for prevention, aligning with World Health Organization (WHO’s) 90-70-90 elimination strategy.

Metrics

Metrics Loading ...

References

World Health Organization (WHO). Cervical Cancer Fact Sheet. 2023. Available at: https://www.who.int/ newsroom/factsheets/detail/cervical-cancer. Accessed on 20 August 2025.

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):20949. DOI: https://doi.org/10.3322/caac.21660

Bruni L, Albero G, Serrano B, Mena M, Collado JJ, Gómez D, et al. HPV and Related Diseases Report. ICO/IARC Information Centre on HPV and Cancer. 2023. Available at: https://hpvcentre.net/statistics/ reports/XWX.pdf. Accessed on 20 August 2025.

International Agency for Research on Cancer (IARC). Ethiopia Cancer Fact Sheets. Globocan. 2022. Available at: https://gco.iarc.who.int/media/ globocan/factsheets/populations/231-ethiopia-fact-sheet.pdf. Accessed on 20 August 2025.

Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, et al. Estimates of incidence and mortality of cervical cancer in 2020: A worldwide analysis. Lancet Glob Health. 2020;8(2):e191203. DOI: https://doi.org/10.1016/S2214-109X(19)30482-6

Okunade KS, Sun K, Okunade A. Risk factors for cervical cancer among African women: A systematic review. J Glob Oncol. 2022;6:1-12.

Bayu H, Berhe Y, Mulat A, Alemu A. Cervical cancer screening service uptake and associated factors among age-eligible women in Ethiopia: A systematic review and meta-analysis. PLoS One. 2021;16(10):e0258209.

Getachew S, Getachew E, Gizaw M, Ayele W, Addissie A, Kantelhardt EJ, et al. Cervical cancer screening knowledge and barriers among women in Addis Ababa, Ethiopia. BMC Womens Health. 2020;20(1):1-8. DOI: https://doi.org/10.1186/s12905-020-00909-7

World Health Organization (WHO). Global Strategy to Accelerate the Elimination of Cervical Cancer as a Public Health Problem. 2020. Available at: https://www.who.int/publications/i/item/9789240014107. Accessed on 20 August 2025.

Rantshabeng P, Kasvosve I, Ndlovu A, Gaseitsiwe S, Moyo S. Prevalence of high-risk human papilloma virus in women with high-grade squamous cell intraepithelial lesions in Botswana using Abbott RealTime HPV assay. PLoS One. 2019;14(1):1-9. DOI: https://doi.org/10.1371/journal.pone.0211260

Derbie A, Mekonnen D, Nibret E, Abebe T, Biadglegne F, Mihret A, et al. Cervical cancer in Ethiopia: a review of the literature. Cancer Causes Control. 2023;34:1-11. DOI: https://doi.org/10.1007/s10552-022-01638-y

Hailegebireal AH, Bizuayehu HM, Tirore LL. Far behind 90-70-90's screening target: the prevalence and determinants of cervical cancer screening among Sub-Saharan African women: evidence from Demographic and Health Survey. BMC Cancer. 2024;24(1):1050. DOI: https://doi.org/10.1186/s12885-024-12789-3

Temesgen T, Adhena G, Figa Z. Precancerous cervical lesion among women in public hospitals of Addis Ababa, Ethiopia. Cancer Res J. 2020;8(4):94-9. DOI: https://doi.org/10.11648/j.crj.20200804.15

Kabir I, Ribeiro RM. HPV and cervical cancer: From molecular diagnostics to emerging treatment approaches (Review). World Acad Sci J. 2025;7(4):58. DOI: https://doi.org/10.3892/wasj.2025.346

Downham L, Jaafar I, Rol ML, Stanczuk G, Kelly H, Michelow P, et al. Accuracy of HPV E6/E7 oncoprotein tests to detect high-grade cervical lesions: a systematic literature review and meta-analysis. Br J Cancer. 2024;130:517-25. DOI: https://doi.org/10.1038/s41416-023-02490-w

Zhang R, Xu W, Yang S, Li Z, Chen X, Wang Y, et al. Prevalence of high-risk human papillomavirus infection, associated risk factors, and relationship with cervical precancerous lesions in perimenopausal and older women in an area with high cervical cancer incidence in China. Cureus. 2024;16(4):e58081. DOI: https://doi.org/10.7759/cureus.58081

Lagos M, Van De Wyngard V, Poggi H, Caceres L, Meza G, Vargas J, et al. HPV16/18 genotyping for the triage of HPV positive women in primary cervical cancer screening in Chile. Infect Agents Cancer. 2015;10:43. DOI: https://doi.org/10.1186/s13027-015-0038-5

Sierra MS, Tsang SH, Hu S, Porras C, Herrero R, Kreimer AR, et al. Risk factors for non–human papillomavirus type 16/18 cervical infections and associated lesions among HPV DNA–negative women vaccinated against HPV-16/18 in the Costa Rica vaccine trial. J Infect Dis. 2021;224(3):503-16. DOI: https://doi.org/10.1093/infdis/jiaa768

Kelly H, Jaafar I, Chung M, Michelow P, Greene S, Strickler H, et al. Diagnostic accuracy of cervical cancer screening strategies for high-grade cervical intraepithelial neoplasia (CIN2+/CIN3+) among women living with HIV: a systematic review and meta-analysis. EClinicalMedicine. 2022;53. DOI: https://doi.org/10.1016/j.eclinm.2022.101645

Baena A, Mesher D, Salgado Y, Martínez S, Villalba GR, Amarilla ML, et al. Performance of visual inspection of the cervix with acetic acid (VIA) for triage of HPV screen‐positive women: results from the ESTAMPA study. Int J Cancer. 2023;152(8):1581-92. DOI: https://doi.org/10.1002/ijc.34384

Bogale AL, Teklehaymanot T, Kassie GM, Medhin G, Ali JH, Belay NB. Performance of visual inspection with acetic acid for cervical cancer screening as compared to human papillomavirus DNA testing among women with HIV in Ethiopia: a comparative cross-sectional study. Cancer Control. 2022;29. DOI: https://doi.org/10.1177/10732748221114980

Bruni L, Albero G, Serrano B, Mena M, Collado JJ, Gómez D, et al. Human Papillomavirus and Related Diseases in Ethiopia. Summary Report 22 October 2021. ICO/IARC HPV Information Centre. 2023. Available at: https://hpvcentre.net/statistics/reports/ ETH.pdf. Accessed on 20 August 2025.

Mekuria M, Edosa K, Endashaw M, Tadesse S, Alemayehu D, Belay F, et al. Prevalence of cervical cancer and associated factors among women attending cervical cancer screening center at Gahandi Memorial Hospital, Ethiopia. Cancer Inform. 2021;20.

Stelzle D, Tanaka LF, Lee KK, Khalil AI, Baussano I, Shah AS, et al. Estimates of the global burden of cervical cancer associated with HIV. Lancet Glob Health. 2021;9(2):e161-71. DOI: https://doi.org/10.1016/S2214-109X(20)30459-9

Rani J, Yadav S, Yadav R, Chhabra R. Hormonal dynamics of cervical cancer: role of estrogen and progesterone. Cell Biochem Funct. 2025;43(5):e70082. DOI: https://doi.org/10.1002/cbf.70082

Teklehaimanot DA, Mekuria AD, Dadi AF, Terefe MW, Kassa GM, Asmare TA, et al. Precancerous lesion determinants in women attending cervical cancer screening at public health facilities in North Shoa Zone, Amhara, Ethiopia: an unmatched case-control study. BMC Womens Health. 2024;24:271. DOI: https://doi.org/10.1186/s12905-024-03113-z

Mekuria M, Edosa K, Endashaw M, Tadesse S, Alemayehu D, Belay F, et al. Prevalence of cervical cancer and associated factors among women attending cervical cancer screening center at Gahandi Memorial Hospital, Ethiopia. Cancer Inform. 2021;20. DOI: https://doi.org/10.1177/11769351211068431

Ferede YA, Tassew WC, Zeleke AM. Precancerous cervical lesion and associated factors among HIV-infected women in Ethiopia: systematic review and meta-analysis. BMC Cancer. 2024;24:678. DOI: https://doi.org/10.1186/s12885-024-12462-9